3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Non-Muscle Invasive Bladder Neoplasms
9
Carcinoma, Transitional Cell
7
Stomach Neoplasms
4
Anus Neoplasms
4
Pancreatic Neoplasms
3
Carcinoma, Hepatocellular
3
Peritoneal Neoplasms
2
Liver Neoplasms
2
Colorectal Neoplasms
2
Appendiceal Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pseudomyxoma Peritonei
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Mycobacterium Infections
1
Gastrointestinal Neoplasms
1
Dermatitis
1
Carcinoma in Situ
1
Carcinoma
1
Anal Canal Carcinoma
1
Adenocarcinoma
1
Interventions
Sunitinib
2
Paclitaxel
2
valrubicin
1
temsirolimus
1
sipuleucel-T
1
luprolide acetate gel depot
1
ferumoxtran-10
1
abiraterone
1
abemaciclib
1
Suspensions
1
Surveys and Questionnaires
1
Standard of Care
1
Radiotherapy
1
Prednisone
1
Prednisolone
1
Powders
1
Pemetrexed
1
Neoadjuvant Therapy
1
National Cancer Institute (U.S.)
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Leuprolide
1
Fatty Acids, Omega-3
1
Educational Status
1
Docetaxel
1
Bevacizumab
1
Atorvastatin
1
Administration, Intravesical
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urogenital Neoplasms
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts